Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.470 -0.150 (-5.73%)
Streaming Delayed Price Updated: 3:17 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
From Pomerantz LLP
Via GlobeNewswire
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns. 
Via Benzinga
Booz Allen, FreshPet, Rocket Pharma Downgraded, While Vail Resorts And FICO Get An Upgrade – Top Wall Street Analyst Calls Today
State Street received an upgrade from Truist, raising the stock to ‘Buy’ from ‘Hold’ and increasing its price target to $112 from $85. 
Via Stocktwits
Topics ETFs Stocks
Exposures Product Safety US Equities
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off This Month
Via Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Via Benzinga
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery
Message volume on Stocktwits spiked to ‘extremely high’ levels, and the ticker added 20% more watchers. 
Via Stocktwits
Topics Death
Exposures Death Product Safety
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
Rocket Pharmaceuticals halted its Danon disease gene therapy trial after a patient death, with the FDA placing the study on clinical hold for review. 
Via Benzinga
Exposures Product Safety
There are notable gap-ups and gap-downs in today's session.
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
Via Benzinga
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible." 
Via Stocktwits
Exposures Product Safety
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst
Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease. 
Via Benzinga
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility
Despite market volatility, these stocks are seeing strong buys by insiders. 
Via Talk Markets
Topics Stocks / Equities
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
Via Benzinga
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.